CORE TECHNOLOGY

Arachidonic Acid (AA) is metabolized by Lipoxygenases (LO), Cyclooxygenases (COX), and Cytochrome P-450s (CYP) to yield biologically active fatty acid oxides (oxylipins).  CYPs can metabolize mono- or poly-unsaturated fatty acids to their epoxy metabolites.  In case of AA, this metabolism can yield mono-epoxides of arachidonic acids (EETs), which have been established to be physiologically beneficial.  Further metabolism of EETs by soluble epoxide hydrolase (sEH) leads to generation of respective vicinal-dihydroxides of respective epoxide.

It has been well established preclinically that inhibiting sEH leads to considerable beneficial effects. OROX Bio Sciences harnesses the beneficial effects of inhibiting sEH in concert with secondary targets in a single molecule to gain synergy in efficacy and bring about resolution to therapeutic areas such as cancer and fibrosis. Numerous in vivo pharmacology studies have revealed the effectiveness of our lead dual inhibitors in reducing growth and metastasis of various tumor types and successfully alleviating pulmonary fibrosis in mice. As this first inhibitor continues into preclinical development, our newly synthesized sEH inhibitors capable of inhibiting secondary targets will be tested for pharmacological activity.